New antibiotic for treatment of MRSA, hopefully on the market soon, meanwhile due to losses in revenue, employee cuts will take place...BD
Theravance announced that it is cutting 40 percent of its workforce now that it has finished work on its antibiotic telavancin. Telavancin is currently undergoing FDA review: in March the FDA accepted the company's response to the approvable letter Theravance received in October. Telavancin is a once-daily injectable antibiotic for the treatment of complicated skin and skin structure infections, such as MRSA.
Drug work completed, Theravance cuts 40% of staff - FierceBiotech
0 comments :
Post a Comment